Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
Status:
Recruiting
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well a combination of three immunotherapy drugs work for
patients with Merkel cell carcinoma that has spread to lymph nodes and/or distant parts of
the body and cannot be treated with surgery (advanced or metastatic MCC) and grew despite
prior PD-(L)1 therapy. The three drugs INCMGA00012 (retifanlimab, anti-PD-1), INCAGN02385
(tuparstobart, anti-LAG-3), and INCAGN02390 (verzistobart, anti-TIM-3) are monoclonal
antibodies given periodically via IV to reactivate the body's immune system to attack the
cancer. This combination may stop tumor growth if tumors have grown despite anti-PD-(L)1
therapy alone.